← Back to Clinical Trials
Recruiting Phase 2 NCT06469970

NCT06469970 Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06469970
Status Recruiting
Phase Phase 2
Sponsor Centre Hospitalier Régional Metz-Thionville
Condition Burns
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2024-11-28
Primary Completion 2027-03-28

Trial Parameters

Condition Burns
Sponsor Centre Hospitalier Régional Metz-Thionville
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 15
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-28
Completion 2027-03-28
Interventions
Glucose 30% Intravenous Solution

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a prospective, observational, monocentric, phase II (exploratory) cohort study aiming to describe the evolutionary profile of the initial volume of glucose distribution (IDVG) during the first four days of management of severely burned patient.

Eligibility Criteria

Inclusion Criteria: * Patients over 18 years of age * Patients hospitalized with burns of at least 30% of body surface area * By a thermal mechanism * At the CHR Metz-Thionville burn center * managed within the 8 hours post-burn * Patient affiliated to a social security scheme * Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion. Exclusion Criteria: * Diabetic patients on insulin * Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection * Patients with pre-hospital cardiac arrest * extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy) * patient without a central venous line or arter

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology